Hans Mauß

from Wikipedia, the free encyclopedia

Hans Mauß , also Mauss (born April 16, 1901 in Barmen ; † April 5, 1953 in Wuppertal -Barmen) was a German pharmacologist at Bayer -Werken (Wuppertal-Elberfeld), known for the development of various chemotherapeutic agents.

After graduating from high school in 1920, Mauß studied chemistry at the University of Marburg , where he received his doctorate in 1925 with Karl Friedrich von Auwers with a dissertation on isomerism in pyrazoles (isomerism phenomena in 3-phenyl-5-chloropyrazole) and then was an assistant (they published et al via acyloine ). From 1927 he was in the pharmaceutical laboratory of Bayer AG in Wuppertal-Elberfeld. This is where his collaboration with Fritz Mietzsch began . Together with Walter Kikuth (Head of Pharmacology), they developed the anti-malaria drug atebrine in 1930 , which was used from 1932 and was used a lot by the Allies during World War II. In contrast to the Plasmochin previously developed at Bayer, it should not act against the gametes , but against the schizonts of the pathogen. After the Second World War, it was replaced by Resochin, developed by Hans Andersag at Bayer, or the closely related chloroquine, which had the advantage of not turning the skin yellow and generally had fewer side effects.

From the late 1930s he and colleagues under Kikuth developed chemotherapeutic agents for schistosomiasis based on xanthones and thioxanthones : Miracil D was used against schistosomiasis in 1953.

In 1934, he and Fritz Mietzsch received the Emil Fischer Medal .

literature

  • Dünschede Tropical Medicine Research at Bayer , Düsseldorf 1971

Web links

Individual evidence

  1. ^ Mauß, von Auwers About Acyloine , Biochemische Zeitschrift, 192, 1928, 200–229
  2. R. Gönnert, H. Kölling, Mauß Studies on Chemotherapy of Schistosomiasis , Medicine and Chemistry, Volume 5, 1956, 185–205
  3. Mauß On basic substituted xanthone and thioxanthone derivatives; Miracil, a new chemotherapeutic agent , Chemical Reports, Volume 81, 1948, pp. 19-31